| |APRIL 20269ABBVIE COMBO TRIAL SHOWS 62 PERCENT RESPONSE IN OVARIAN CANCERRG HOSPITALS, NEW DELHI, SUCCESSFULLY REMOVES MASSIVE 77 × 65 MM BLADDER STONECAN DCGI'S NEW BIOSIMILAR GUIDELINES FLIP THE PHARMA GAME OVERNIGHT?BOTANIC HEALTHCARE APPOINTS PHARMA VETERAN KAMALAKAR V. ARCOT AS GROUP CEO TO DRIVE GLOBAL EXPANSIONAbbVie has shared promising results from a Phase 2 clinical trial testing a new combination treatment for ovarian cancer, offering fresh hope for patients with limited options.The study evaluated mirvetuximab soravtansine-gynx, a targeted therapy, used alongside chemotherapy (carboplatin), followed by continued treatment with the same drug. The trial focused on patients with platinum-sensitive ovarian cancer (PSOC) whose tumors showed high levels of folate receptor alpha (FR), a key marker linked to better treatment response.The results showed an objective response rate of about 62 Percent, meaning a significant number of patients saw their tumors shrink or respond positively to the treatment. This is particularly encouraging in ovarian cancer treatment, where relapse after initial therapy is common. PONew Delhi, 15th April 2026: In a remarkable display of surgical precision, RG Hospitals at its Gagan Vihar centre has successfully removed a massive 77 × 65 mm bladder stone, one of the largest recorded, restoring a 33-year-old man's life to normal. Led by Dr. Manoj Jain, HOD & Chief Urologist, alongside Dr. Ajay Aggarwal, Consultant Urologist, and a skilled OT team, the daring open cystolithotomy ensured 100% stone clearance in a single procedure.The 33-year-old patient had endured months of agony, relentless lower abdominal pain, urgent and frequent trips to the bathroom, symptoms that had worsened over 6-7 months. Initial ultrasound and clinical checks uncovered the enormous vesical calculus, coupled with bladder inflammation (cystitis), demanding immediate action to prevent life-threatening complications. POIndia is set to overhaul how biosimilar drugs are approved, with regulators proposing a major shift that could cut costs, speed up access, and reshape the pharmaceutical landscape.Botanic Healthcare has appointed Kamalakar V. Arcot as its Group Chief Executive Officer, in a move aimed at strengthening its global expansion strategy in the nutraceutical and bioactives segment.A seasoned executive with over two decades of experience in the global pharmaceutical and life sciences industries, Mr. Arcot brings deep expertise in scaling businesses According to a report, DGCI is working on new biosimilar guidelines that would ease long-standing requirements around bioequivalence studies--one of the most time-consuming and expensive parts of drug development.across regulated and emerging markets. In his new role, he will lead Botanic Healthcare's strategic vision, drive international expansion, and strengthen operational excellence across geographies.Arcot has an extensive track record of managing complex P&L responsibilities across North America, Latin America, Europe, Asia Pacific, and the Middle East. His experience spans the entire pharmaceutical value chain from strategic portfolio development and intellectual property management to supply chain optimization and large-scale commercial execution. POSpeaking at the ninth edition of India Pharma 2026, Dr Rajeev Raghuvanshi informed that based on recommendations received on the draft issued last year "the final guidelines will reduce the need for separate bioequivalence studies and rely more heavily on characterization to demonstrate equivalence with the innovator product." PO
< Page 8 | Page 10 >